During Jazz Pharmaceuticals’ earnings call, CEO Bruce Cozadd highlighted the company’s focus on expanding its business through strategic deals. Jazz plans to broaden its range of products by exploring opportunities in neuroscience, cancer treatments, and other rare diseases. The company is also considering factors like revenue stability and efficient sales strategies.
Cozadd shared good news about Jazz’s key product, Epidiolex, a CBD medication for seizures. The company reached agreements with generic drug makers, delaying their versions of Epidiolex until the late 2030s. This ensures a steady income from Epidiolex and could encourage Jazz to pursue more mergers and acquisitions (M&A). Epidiolex sales are expected to hit blockbuster levels, nearing $1 billion this year.
Jazz acquired Epidiolex through a $7.2 billion deal with GW Pharmaceuticals in 2021. Although no major deals have been announced since then, Jazz’s CFO, Philip Johnson, assured that the company is actively seeking new opportunities. For 2025, Jazz forecasts revenues between $4.15 billion and $4.4 billion, with a 5% growth from the previous year.
Jazz’s financial strength allows it to engage in M&A and licensing activities. Cozadd expressed readiness to expand the company’s product lineup. Another drug, the HER2 bispecific Ziihera, was acquired through a deal with Zymeworks. Recently approved for a type of cancer, Ziihera could achieve over $2 billion in peak sales.
Jazz postponed the release of study results for Ziihera in another cancer type to the end of 2025 due to slower-than-expected progress in the trial. Meanwhile, Cozadd plans to retire as CEO by the end of 2025 but will remain as chairman. He emphasized the need to carefully select his successor without rushing the process.